ACE and hydrops fetalis: Although a number of life-saving therapeutic strategies have been implemented in the last two decades, both pharmaceutical (ACE-inhibitors, ARB, ARNI, beta-blockers, mineralocorticoid antagonists) and interventional (primary percutaneous coronary intervention, cardiac resynchronization therapy, implantable cardioverter-defibrillators, and left ventricular assist devices), recent data from the ESC-HFA Heart Failure Long-Term Registry (ESC-HF-LT) revealed 1-year all-cause mortality rates of 23.6% for hospitalized HF (HHF) and 6.4% for chronic HF (CHF) [4].